<DOC>
	<DOC>NCT01026415</DOC>
	<brief_summary>The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).</brief_summary>
	<brief_title>Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Adequate organ function (Special Populations: serum bilirubin &gt;2 mg/dL or creatinine clearance &lt;50 mL/min) ECOG performance status &lt;2 (Special Populations: &lt;4) Relapsed or refractory CD30positive malignancy Receiving prohibited medication within 4 weeks Poor liver function (ChildPugh class C) Current diagnosis of primary cutaneous ALCL Acute or chronic graftversushost disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Disease, Hodgkin</keyword>
	<keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
</DOC>